| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2017-10-03 |
| タイトル |
|
|
タイトル |
Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| ID登録 |
|
|
ID登録 |
10.24517/00014305 |
|
ID登録タイプ |
JaLC |
| 著者 |
Terashima, Takeshi
Yamashita, Tatsuya
Takata, Noboru
Nakagawa, Hidetoshi
Toyama, Tadashi
Arai, Kuniaki
Kitamura, Kazuya
Yamashita, Taro
Sakai, Yoshio
Mizukoshi, Eishiro
Honda, Masao
Kaneko, Shuichi
|
| 著者別表示 |
寺島, 健志
山下, 竜也
遠山, 直志
荒井, 邦明
北村, 和哉
山下, 太郎
酒井, 佳夫
水腰, 英四郎
本多, 政夫
金子, 周一
|
| 提供者所属 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
先進予防医学研究センター / 金沢大学附属病院 |
| 書誌情報 |
Hepatology Research
巻 46,
号 7,
p. 650-656,
発行日 2016-06-01
|
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1386-6346 |
| NCID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA11140867 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1111/hepr.12601 |
| 出版者 |
|
|
出版者 |
Blackwell Publishing Ltd. |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Aim: Although sorafenib is a standard drug for advanced hepatocellular carcinoma (HCC), little is known about a patient's clinical course after treatment. We investigated the effect of post-progression survival (PPS) and progression-free survival (PFS) on overall survival (OS) in patients whose advanced HCC was treated by sorafenib. Methods: We searched in the PubMed database for reports with survival data of patients with HCC treated with sorafenib monotherapy, and selected reports with 20 or more patients each that provided data for both OS and PFS or time to progression (TTP). Median PPS (mPPS) was defined as the period obtained by subtracting median PFS or TTP (mPFS/TTP) from median OS (mOS). We identified 56 reports with 5803 patients. We investigated the correlation of mOS and either mPPS or mPFS/TTP using weighted linear regression. Results: Median PPS correlated with mOS (r=0.834) very strongly, whereas mPFS/TTP did not correlate with mOS as highly as PPS did (r=0.546). When we stratified survival data by Child-Pugh classification, a significantly greater average percentage of mPPS to mOS was seen in Child-Pugh class A (54.4±17.6%) than in Child-Pugh class B (32.0±11.6%) (P=0.015). Conclusion: PPS highly correlated with OS, and its importance should be more emphasized for advanced HCC patients treated after sorafenib therapy, whereas we need to take more care in interpreting the results of PFS to evaluate treatment efficacy in clinical trials of advanced HCC. © 2015 The Japan Society of Hepatology. |
| 内容記述 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Embargo Period 12 months |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
ME-PR-TERASHIMA-T-650.pdf (684.8 kB)
.png)
